Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has more than 25 years of diverse experience in the pharmaceutical industry, including holding several management positions. Most recently, Dr. Suzdak was chief scientific officer (CSO) of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was cofounder, CEO and CSO of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was president and CEO of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as senior vice president of research and development of Guilford Pharmaceuticals, which developed therapeutics and diagnostics for neurological diseases and cancer, and as director of neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.